The global Oral Solid Dosage (OSD) Contract Manufacturing Market is experiencing robust growth, driven by increasing pharmaceutical outsourcing, rising demand for cost-effective drug production, and the continual evolution of advanced drug delivery technologies. Oral solid dosage forms—tablets, capsules, powders, and granules—remain the most preferred drug delivery format due to their stability, convenience, and cost-efficiency. As pharmaceutical companies continue to shift focus towards core competencies like R&D and marketing, the reliance on contract development and manufacturing organizations (CDMOs) for OSD formulation is significantly rising.
Market Overview
Global Oral Solid Dosage Contract Manufacturing Market size and share is currently valued at USD 37.82 billion in 2024 and is anticipated to generate an estimated revenue of USD 57.02 billion by 2032 , according to the latest study by Polaris Market Research. Besides, the report notes that the market exhibits a robust 5.3% Compound Annual Growth Rate (CAGR) over the forecasted timeframe, 2024 – 2032
The market’s expansion is also being catalyzed by the growing complexity of modern oral formulations, regulatory pressure, and the rising demand for high-potency drugs. CDMOs provide specialized expertise in tablet manufacturing, coating, packaging, and clinical trial supply, thereby helping pharmaceutical clients streamline their production pipelines while maintaining quality and regulatory compliance.
Key Market Growth Drivers
1. Surge in Pharmaceutical Outsourcing
Pharmaceutical outsourcing has emerged as a core strategy for cost optimization and efficiency in drug development and production. Many biopharmaceutical and generic drug companies prefer contract manufacturing partners to avoid the high costs associated with facility maintenance, labor, and compliance. This trend is particularly evident in the production of oral solid dosage forms due to their standardized, scalable nature.
2. Increasing Demand for Generic Drugs
The expiration of key drug patents and the rising healthcare burden in developing nations have contributed to a surge in the generic drugs market. Contract manufacturers, equipped with ready infrastructure for large-volume production and experience in bioequivalence studies, are essential partners in bringing affordable generics to market quickly and efficiently.
3. Expansion of Clinical Trial Supply Chains
CDMOs play a pivotal role in supplying oral solid dosage forms for clinical trials, especially in Phase II and III. The ability to produce small-to-medium-scale batches with adherence to regulatory compliance requirements makes CDMOs ideal for managing the complexities of clinical trial supply. This demand is further fueled by increasing R&D activities globally.
4. Technological Advancements in Formulation
Recent innovations in extended-release and targeted drug delivery systems are expanding the application of OSDs in complex treatment regimens. These advancements require specialized formulation techniques and infrastructure, which CDMOs are investing in to gain competitive advantages. Technologies such as hot-melt extrusion and fluid bed granulation are increasingly being adopted.
Market Challenges
Despite its strong growth outlook, the OSD contract manufacturing market faces several challenges:
-
Regulatory Scrutiny: Compliance with evolving international regulatory standards (e.g., FDA, EMA) is a critical challenge for manufacturers. CDMOs must maintain state-of-the-art quality management systems and demonstrate consistent adherence to good manufacturing practices (GMP).
-
Capacity Constraints: The increasing demand for contract manufacturing sometimes outpaces available production capacity, particularly in specialized segments like high-potency drugs.
-
Supply Chain Disruptions: Events like pandemics, geopolitical instability, and raw material shortages can severely impact the supply chain, posing significant risks to production timelines and consistency.
-
Intellectual Property Concerns: In partnerships involving novel drug formulations, pharmaceutical companies may hesitate to fully outsource due to concerns around IP protection and confidentiality.
Browse Full Insights:
Regional Analysis
North America
North America holds the largest share of the OSD contract manufacturing market, accounting for over 35% of the global market in 2024. The region’s dominance is attributed to a high concentration of pharmaceutical companies, advanced infrastructure, and a strong regulatory framework. The U.S. in particular benefits from the presence of leading CDMOs and a robust generics market.
Europe
Europe follows closely, with strong demand from the United Kingdom, Germany, and France. The presence of multiple small and medium-sized pharma companies that prefer outsourcing, combined with stringent regulatory oversight by the EMA, drives the need for high-quality CDMO services in this region.
Asia Pacific
The Asia Pacific region is expected to witness the fastest growth over the forecast period. Countries such as India and China are emerging as contract manufacturing hubs due to their cost advantages, skilled workforce, and expanding regulatory capabilities. The rise of domestic pharmaceutical firms and government incentives for contract manufacturing in countries like South Korea and Japan further bolster regional growth.
Latin America and Middle East & Africa
These regions are gradually catching up, with increasing pharmaceutical investments and the expansion of multinational CDMO operations. Brazil and South Africa are anticipated to be the key growth markets due to healthcare system reforms and rising demand for generics.
Key Companies in the Market
The global OSD contract manufacturing landscape is moderately consolidated, with several major players and numerous mid-sized firms. Some of the key companies include:
-
Catalent Inc. – A market leader known for its capabilities in complex OSD formulations and global clinical trial supply chain services.
-
Lonza Group AG – Offers end-to-end services from development to commercialization, including advanced OSD technologies.
-
Thermo Fisher Scientific Inc. (Patheon) – Provides extensive manufacturing services and regulatory support for both branded and generic oral solids.
-
Recipharm AB – Known for its flexible manufacturing services across Europe and focus on tailored solutions for small to mid-sized clients.
-
Piramal Pharma Solutions – Offers specialized high-potency OSD manufacturing and strong presence in North America and India.
-
Aenova Group, Almac Group, Strides Pharma Science, and DPT Laboratories are also notable contributors to market growth with diverse service portfolios.
Future Outlook
As the global healthcare landscape evolves, the need for scalable, compliant, and technologically advanced manufacturing solutions continues to rise. CDMOs that can invest in innovation, navigate regulatory complexities, and deliver quality at scale will continue to capture significant market share.
The growing demand for pharmaceutical outsourcing, along with rising complexity in tablet manufacturing and expanding global clinical trial supply networks, positions the OSD contract manufacturing market for sustained growth. CDMOs that prioritize regulatory compliance and invest in flexible production platforms will be the key enablers of future pharmaceutical innovation.
More Trending Latest Reports By Polaris Market Research:
